Max Colao, OncoVerity CEO
Tiny multiomics biotech secures former J&J drug, new execs and new financing
A new spinout from Belgium’s argenx seeks to give new life to a candidate once in-licensed to J&J.
OncoVerity announced Monday afternoon that it had in-licensed cusatuzumab from argenx. The biotech also appointed two new C-suite executives and secured a $30 million Series A round.
CEO Max Colao joins OncoVerity after working as Aurinia’s commercial chief, and stints at Alexion and Amgen. New CMO Clay Smith has been associate chief of the University of Colorado’s hematology division.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters